The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma

Biomedicine and Pharmacotherapy

Volumn 65, Issue 3, 2011, Pages 168-174

  Zuo, Qiang ^a   Shi, Min ^a   Chen, Jinzhang ^a   Liao, Wangjun ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cetuximab; Drug resistance; Nasopharyngeal carcinoma

Indexed keywords

CETUXIMAB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C FOS; PROTEIN KINASE B; RAS PROTEIN; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; NUCLEOPROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 79959640290     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.02.005     Document Type: Article

References (29)

1. Wang Y., Minoshima S., Shimizu N. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. Jpn J Hum Genet 1993, 38:399-406.
2. Raoul J.L., Van Laethem J.L., Peeters M., Brezault C., Husseini F., Cals L., et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009, 9:112.
3. Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008, 28:742-754.
4. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
5. Normanno N., Tejpar S., Morgillo F., De Luca A., Van Cutsem E., Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009, 6:519-527.
6. Chan A.T., Hsu M.M., Goh B.C., Hui E.P., Liu T.W., Millward M.J., et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005, 23:3568-3576.
7. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
8. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
9. Zuo Q., Shi M., Li L., Chen J., Luo R. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. Biomed Pharmacother 2010, 64:550-558.
10. Van Cutsem E., Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):49-50.
11. Rubin Grandis J., Melhem M.F., Barnes E.L., Tweardy D.J. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996, 78:1284-1292.
12. Ang K.K., Andratschke N.H., Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004, 58:959-965.
13. Rubin Grandis J., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832.
14. Egloff A.M., Grandis J.R. Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009, 2009:896407.
15. Chou C.C., Chou M.J., Tzen C.Y. PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol 2009, 26:322-326.
16. Coutinho C.M., Bassini A.S., Gutierrez L.G., Butugan O., Kowalski L.P., Brentani M.M., et al. Genetic alterations in Ki-ras and Ha-ras genes in juvenile nasopharyngeal angiofibromas and head and neck cancer. Sao Paulo Med J 1999, 117:113-120.
17. Fecher L.A., Amaravadi R.K., Flaherty K.T. The MAPK pathway in melanoma. Curr Opin Oncol 2008, 20:183-189.
18. Lawrence M.C., Jivan A., Shao C., Duan L., Goad D., Zaganjor E., et al. The roles of MAPKs in disease. Cell Res 2008, 18:436-442.
19. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
20. Toker A., Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006, 66:3963-3966.
21. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204.
22. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744.
23. Liss A.S., Tiwari R., Kralova J., Bose H.R. Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappaB oncogenesis. Oncogene 2010, 29:4925-4937.
24. Minden A., Lin A., Smeal T., Derijard B., Cobb M., Davis R., et al. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol 1994, 14:6683-6688.
25. Qiao L., Han S.I., Fang Y., Park J.S., Gupta S., Gilfor D., et al. Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol 2003, 23:3052-3066.
26. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
27. Verma I.M., Stevenson J.K., Schwarz E.M., Van Antwerp D., Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995, 9:2723-2735.
28. Yang M.D., Lai K.C., Lai T.Y., Hsu S.C., Kuo C.L., Yu C.S., et al. Phenethyl isothiocyanate inhibits migration and invasion of human gastric cancer AGS cells through suppressing MAPK and NF-kappaB signal pathways. Anticancer Res 2010, 30:2135-2143.
29. Carmona E.M., Lamont J.D., Xue A., Wylam M., Limper A.H. Pneumocystis cell wall beta-glucan stimulates calcium-dependent signaling of IL-8 secretion by human airway epithelial cells. Respir Res 2010, 11:95.